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1. Introduction 
1.1 History 
The foundation for lung transplantation was laid in the early 1900 by Guthrie and Carrel. 
In recognition of his work in vascular anastomosis, Dr. Carrel received the first Nobel 
Prize in Medicine. Following this early work, in 1946 Demikov in Russia performed a 
canine lung transplant as a unit. The dog subsequently died of bronchial dehiscence. The 
first human lung transplant was performed by Hardy at the University of Mississippi in 
1963. Patient survived a few days and succumbed to complications. Derom in Belgium 
was credited with the first successful human lung transplantation when he reported 10 
month survival of a patient who had undergone lung transplant for end-stage pulmonary 
fibrosis in 1971. By 1978, 38 lung transplants had been performed worldwide but Derom’s 
patient was the only one that had approached a beneficial outcome. Consistently noted 
poor outcome in the 60s and 70s led to a moratorium on clinical lung transplantation  
in the late 70s. Rejection and infection were the common causes of death in this early 
group and bronchial anastomotic healing was the barrier for transplant survival beyond 2 
weeks (1).  
Cyclosporine based immune suppression in kidney and liver transplantation in the early 
1980s resulted in dramatic improvements in organ function and patient survival. With this 
experience Shumway and Reitz successfully transplanted heart-lung blocks using a 
cyclosporine based immune suppression on primates. Airway complications were rare in 
heart-lung transplantation due to the non coronary collaterals, where as this was a major 
drawback of isolated lung transplantation. The success of the Stanford group led to the 
reinstitution of clinical heart-lung transplantation in the 80s (2).  
Meanwhile in Toronto, significant experimental work were done by Pearson and Cooper 
to solve the bronchial healing problem in animal models. The technique of omental wrap 
around the bronchial anastomosis was developed by Cooper et al. In 1986 the Toronto 
Lung Transplant Group reported successful single lung transplantation for pulmonary 
fibrosis in two patients (3). Technique of en-bloc double lung transplant failed due to the 
tracheal anastomotic complication related to ischemia. Finally bilateral sequential 
transplantation was developed as a method of transplanting both lungs without the heart. 
Currently around 147 centers perform over 2000 isolated lung transplants a year. The 
bronchial anastomotic technique has evolved since and bronchial wrapping is no longer 
considered necessary.  
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2. Patient selection for lung transplantation 
2.1 Indications 
Lung transplant is indicated for patients with chronic, end-stage lung disease for whom no 
effective medical therapy is available (4,5). The primary goal of lung transplantation is to 
provide a survival benefit. Such benefit can be conferred to patients with advanced 
pulmonary fibrosis, cystic fibrosis and primary pulmonary hypertension. Reports for 
emphysema are conflicting and for Eisenmenger’s syndrome transplant did not find a 
survival benefit. However, as lung transplantation is a palliative treatment, improvements 
in quality of life in addition to survival benefit should be used to assess effectiveness of this 
therapy. 
2.2 Contraindications 
2.2.1 Major contraindications 
A history of malignancy during the past two years, except for skin cancers. In general 5 year 
disease free survival is expected (4). 
Untreatable advanced disease of another organ system, except the heart, where a heart-lung 
transplantation could be considered. 
Untreatable extra-pulmonary infections, including chronic, active viral hepatitis and HIV 
infection. 
Significant chest deformity. 
Unreliable social support, medical non-compliance or major psychiatric or psychological 
disorder. 
Active substance abuse or use within the past 6 months. 
2.2.2 Relative contraindications 
Older age; older patients have less optimal survival following lung transplantation. 
Critical or unstable conditions, such as Extra Corporeal Membrane Oxygenation or 
mechanical ventilation. 
Severely limited functional class with poor rehabilitation potential. 
Colonization with highly virulent or antibiotic resistant organism. 
Obesity or malnutrition (BMI>30 or BMI<17). 
Mechanical Ventilation except in carefully selected patients 
Severe or untreated gastroesophageal reflux disease. 
2.3 Timing of referral 
In general referral for transplantation evaluation is recommended when the patient’s median 
survival (50%) is about 2 years or less or New York Heart Association class 3 or 4. Due to the 
natural history of underlying disease, the referral time will depend on the underlying disease. 
The waiting period for transplant depends on underlying disease, waiting time, blood group, 
height of patient and presence of pre-formed antibodies in the recipient.  
3. Lung transplantation procedure 
3.1 Donor selection and operation 
The donor is evaluated for ABO compatibility, size, medical and social history, function, 
associated pathological findings on CXR or CT scan and bronchoscopic findings. Given the 
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improvements in clinical results and shortage of donor organs the generally accepted donor 
criteria are continually being challenged and expanded. Donor lung selection also depends 
on subjective assessment at the time of exploration in the operating room and judgment of 
the donor surgical team (6).  
The donor pneumonectomy is approached via a midline sternotomy. The lung is inspected to 
evaluate its suitability for transplantation by the donor surgical team. Heparin is administered 
and a pulmonary plegia cannula is inserted into the main pulmonary artery ensuring both 
main pulmonary arteries are perfused by the cannula. A clamp is placed on the left atrial 
appendage and the tip of the appendage is excised for free drainage of the pulmonary effluent 
during the pulmonary plegic infusion. Prostaglandins and pulmonary vasodilators are 
administered into the main pulmonary artery followed by cold pulmonary plegia that also 
contains vasodilator medications. The lung is inflated to moderate amount and the trachea is 
stapled with lung inflated. The lung block is dissected away from the mediastinal structure 
with the heart or separately after the heart is excised by the ‘cardiac’ team. Left atrium is 
divided midway between the confluence of the pulmonary veins and the atrial groove 
ensuring that an adequate “atrial cuff” will be available with the lungs for implantation. The 
ligamentum arteriosum is divided toward the descending aorta avoiding injury to the left 
main pulmonary artery and the entire lung block is dissected away from the descending aorta 
and esophagus. The lungs are separated from each other at the back table by dividing the left 
main bronchus with the staples, pulmonary artery at the bifurcation, and left atrium between 
the right and left pulmonary veins. Retrograde cold flush of the preservation solution is 
performed through the pulmonary veins before packaging the organs in sterile fashion for 
transportation to the recipient operating room (8,9).  
Satisfactory early and midterm outcomes had been reported with using lung donation after 
cardiac death expanding potential lung donors (10). Recent exciting developments on 
normothermic ex-vivo perfusion allowing repair of injured lung and the ability to evaluate 
function of the lung prior to transplantation has potential benefit of increasing the donor 
pool even further (11). 
 
Age < 60 
ABO Compatibility 
Clear Chest Radiograph 
PaO2 > 300 on FIO2 = 1.0 and PEEP of 5 cm H2O 
Tobacco history < 20 pack years 
Absence of significant chest trauma 
No evidence of sepsis or blood borne infections (Hepatitis B, C or HIV) 
Prior cardiopulmonary surgery 
Presence of lung pathology on CT scan 
Purulent secretion on bronchoscopy or evidence of aspiration
Table 1. Established Criteria for Donor Selection 
3.2 Recipient operation 
3.2.1 Single lung transplant 
Once a donor is verified and deemed suitable for transplant, the recipient is brought into the 
operating room for transplantation (12). Generally the contra-lateral lung is used to support 
the recipient during the transplantation procedure. Some patient will require 
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cardiopulmonary bypass to perform the lung transplantation safely. General anesthesia is 
provided via a double lumen endo-tracheal tube, a left sided tube is preferred thus avoiding 
the potential complication of obstructing the right upper lobe orifice. Following placement 
of arterial and venous access lines as well as a Trans-esophageal Echo (TEE) probe, the 
patient is placed in a lateral decubitus position, with groin exposed on the same side to 
allow canulation of femoral vessels, if needed. A variety of incisions may be used to enter 
the thorax including a posterolateral incision, anterior submammary incision, or a lateral 
incision that either spares or partially divides the muscle.  
Hilar dissection is performed exposing the pulmonary vessels while preserving the phrenic 
nerve. Vagus neurovascular bundles are carefully preserved particularly on the left side 
where the recurrent laryngeal nerve emerges and encircles the ligamentum arteriosus. The 
recurrent laryngeal nerve may be injured during the dissection of the left main pulmonary 
artery and a heightened awareness of this will help to avoid injury. Dissection around main 
bronchus is kept to minimum to preserve its blood supply. The pericardium is opened 
around the pulmonary veins to release the left atrium for placement of vascular clamp. 
When the donor lung is in the room the recipient is given heparin intravenously and the 
pulmonary veins and artery are divided as distal as possible. We use a linear cutting 
vascular stapler. The main bronchus is divided at the lobar branch level initially and then 
divided with a sharp knife about 2-3 cartilage rings from the carina.  
At the back table, final dissections are made to the donor lung. This includes removal of 
excess mediastinal tissue, mobilization of the main pulmonary artery and the left atrial and 
venous structures from pericardial attachments. We perform a repeat cold retrograde 
flushing of the pulmonary vascular bed with the preservation solution prior to implantation 
to evacuate any residual debris from the pulmonary vascular bed and improve preservation 
(9).  The main bronchus of the donor is opened and microbiological specimens are collected. 
The bronchus is then divided with a knife leaving two rings of cartilage from the origin of 
the upper lobe bronchus. The donor lung is then brought to the operative field. We perform 
the bronchial anastomosis as to “frame” the lung in position first. The membranous portion 
of the bronchus is anastamosed using a running 4-0 absorbable monofilament suture while 
the cartilaginous portion is secured with interrupted figure-of-eight suture of the same type. 
Single-running suture techniques have also been described in the literature and appear to be 
equally effective. Next, attention is turned to the venous anastomosis. A vascular clamp is 
placed along a portion of the left atrium and the recipient left pulmonary vein orifices are 
connected by dividing the bridge of atrial tissue in-between to create a single oval “atrial 
cuff”. The donor atrial cuff is then anastamosed to the recipient atrial cuff in an end-to-end 
fashion using a single, double-armed running 4-0 polypropylene suture. Finally the 
pulmonary artery is prepared for the final anastomosis. Excess length of pulmonary artery is 
removed after appropriately sizing the vessel. This is particularly important on the right 
side, as there is a long length available on the donor. The donor pulmonary artery is 
anastomosed to the recipient in an end-to-end fashion with a single, double-armed running 
5-0 polypropylene suture. Occasionally, a size mismatch exists where the recipient 
pulmonary artery is larger than the donor pulmonary artery. In this case, the larger inferior 
pulmonary trunk arising from the main pulmonary artery is anastomosed end-to-end with 
the donor main pulmonary artery. In this situation the upper branch is divided flush with 
the main artery to prevent any clots forming in the ‘blind-end’. Attention is paid to keep the 
donor lung cold during the entire period using ice slush and cold sponges, until reperfusion. 
Bolus of solumedrol is given intravenously (we give 500 mg) prior to reperfusion of the 
graft. In preparation for reperfusion, the patient is placed in the Trendelenberg position, air 
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and debris are vented through the pulmonary artery anastomosis first. Then pulmonary 
plegia solution is allowed to vent from the left atrial cuff anastomosis by releasing the 
arterial clamp to allow a slow flush. While the left atrium is observed by TEE for air bubbles 
the left atrial clamp is removed and the anastomosis is secured. The reperfusion is 
controlled by slow release of the arterial clamp and any hypotension is treated promptly by 
alpha-agonists. The lung is inflated while monitoring the left atrium on TEE. A leak test may 
be performed at this time by carefully ventilating the new lung with the bronchus 
submerged in warm normal saline and inspecting for air bubbles. After placement of chest 
tube, with satisfactory hemostasis, hemodynamics and oxygenation the chest is closed in 
layers with absorbable sutures. With the patient in the supine position the double-lumen 
endotracheal tube is changed to a single lumen tube and a fiber-optic bronchoscopy is 
performed to inspect the bronchial anastomosis and remove any clots or secretions present 
in the bronchial tree.  
3.2.2 Bilateral sequential lung transplant  
A bilateral anterolateral thoracotomy is a preferable incision for bilateral sequential lung 
transplant as it preserves the structural integrity of the sternum and prevents significant 
incision-related morbidity (13). In a patient with small chest cavity or when there is 
potential need for cardiopulmonary bypass, a clamp-shell incision is made dividing the 
sternum across for the transplantation. The dissection of the lung and the donor lung 
preparation is performed as described above. The lung with the lesser physiologic 
contribution is transplanted first as the other lung support single-lung ventilation.  
The single lung transplants are performed sequentially while the patient is supported by the 
contra-lateral lung. If the operation is being performed without cardiopulmonary bypass 
(CPB), it is important to stabilize the patient after the first lung implantation before 
proceeding with the next. Following implantation of the second lung and patient stable, 
chest tubes are placed and sternum approximate using metal plates or sternal wires. Then 
the wound is closed in layers with absorbable sutures.  
4. Post-operative management 
Patient undergoing lung transplantation requires a team of caregivers who are committed, 
familiar with the protocols and able to ensure ongoing communication between members of 
the team. The team members include, transplant coordinators, transplant pulmonologist, 
transplant surgeon, anesthesiologist, pain management team, critical care specialist, ICU 
nurses, Infectious disease specialist, pharmacologist, physical and occupational therapist, 
nutritionist and social worker. Clinical pathways are developed addressing complete patient 
care with incorporation of immunosuppressive and infection prophylaxis protocols (14). 
Despite clinical pathways, regular team meeting discussing daily care of patient facilitate 
efficient and timely interventions and improve post-operative care.  
5. Respiratory management 
Despite advances in the donor management and preservation of lung, primary graft 
dysfunction is not uncommon following lung transplantation (15). In the majority however 
the degree of dysfunction is minor to moderate and reversible, therefore does not progress 
to graft failure. The incidence of primary graft dysfunction has been reported between 11-57 
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% (16). When there is primary graft failure, extra corporeal membrane oxygenation (ECMO) 
may be required. Early institution of ECMO had been shown to be more successful than late 
(17-19). When the graft dysfunction is mild to moderate, management strategies are 
employed as used in patients with significant lung injury.  
The ventilatory management would be influenced, if the patient received a single or bilateral 
lung transplant. In patients with bilateral lung transplant it would be aimed at minimizing 
barotraumas by using low inflation volumes and moderate levels of positive end expiratory 
pressure (PEEP, less than 10 cm water). In patients with single lung transplant the patho-
physiology of the remaining native lung will influence ventilatory strategy. Significant air 
trapping and auto PEEP is not uncommon in patients with emphysema. Low ventilatory 
volumes, adequate expiratory time and avoidance of excessive PEEP will help to prevent air 
trapping and significant hemodynamic instability in these patients. Positioning patients with 
the allograft side up and bronchodilator therapy are useful strategies in patients with single 
lung transplant. Very rarely isolated lung ventilation with double lumen tube is necessary to 
effectively ventilate when there is significant graft dysfunction.  
Inhaled Nitric Oxide (NO) through the ventilator has been shown to reduce reperfusion 
injury in experimental models and clinical transplantation, when used as prophylaxis. It’s 
usefulness in established graft dysfunction is controversial. Selective use of inhaled NO in 
peri-operative period in patients with pre-existing pulmonary hypertension is not an 
uncommon practice. The aim of the inhaled NO use is to reduce pulmonary artery pressures 
during the operation and immediately afterwards thereby assisting the right ventricular 
function. 
As a rule aggressive weaning off the ventilator is practiced following lung transplantation to 
prevent nosocomial infection and promote early rehabilitation. Sedation should be carefully 
monitored and sparingly used. It is advisable to use short acting agents while patient is 
intubated. Majority of the patients are extubated within the first 24 hours after 
transplantation. After extubation we advocate use of epidural analgesia and avoidance of 
narcotics and benzodiazepines. Aggressive bronchial hygiene is mandatory to prevent 
collapse and development of pneumonia. While patients are intubated using soft suction 
catheters to clear secretion should be performed routinely. Once the patient is extubated 
incentive spirometry, chest physiotherapy and ambulation are necessary to promote 
clearance of bronchial secretions. In patients who are debilitated and have retention of 
secretion we have employed ‘mini-tracheostomy’ to facilitate removal of the secretion with a 
soft tip 10 french catheter. Alternatively patients will require repeat bronchoscopic suction 
of secretions. When a patient fails trial extubation, early tracheostomy facilitates rapid 
weaning of ventilation, assist in effective management of secretions and promote early 
physical rehabilitation. 
6. Hemodynamic management  
Patients selected for lung transplant undergo a detailed cardiac evaluation. Isolated single 
vessel coronary artery disease alone is not a contra-indication for lung transplantation. 
These patients would be candidates for pre-transplantation, percutaneous revascularization 
or would be candidates for simultaneous surgical re-vascularization (19,20). Correctable 
cardiac lesions such as ASD or simple VSD they are repaired during lung transplantation. 
Patients with primary or secondary pulmonary hypertension will have varying degrees of 
right ventricular dysfunction but this improves with successful lung transplantation. Peri-
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operative use of inhaled NO or other pulmonary vasodilator pharmacotherapy is not 
uncommon and certainly useful to reduce post-operative pulmonary hypertension and the 
fluctuations in pressures and reduce the hemodynamic instability.  
The most common hemodynamic disturbance following lung transplantation is hypotension 
and supra-ventricular tachyarrhythmia. The principle of keeping these patients in a relative 
hypovolemic status, make them susceptible to hypotension, if there is any degree of 
vasodilation. It is important to maintain adequate intravascular volume to maintain 
adequate cardiac output as well as urine output. The fluid therapy is aimed at maintaining 
low or low normal cardiac filling pressures. It is however not necessary to monitor 
pulmonary artery wedge pressures in all patients and monitoring of right atrial filling 
pressures are most often adequate. The fact that the lymphatic drainage is interrupted from 
the lung allograft following transplantation, any capillary leak in to the lung parenchyma 
will be cleared less efficiently. It had been shown that fluid restriction in patients with lung 
injury promotes early recovery (21). This may be an important factor to consider during the 
post operative period, due to the fact that majority of the lung grafts suffer some degree of 
reperfusion injury. Systemic vasodilation whether it is produced by medications or 
sympathetic blockade due to epidural or release of cytokines, best treated with 
vasoconstriction using intravenous short acting alpha-blockers than by volume. 
Neosynephrine is the drug of choice in the treatment of systemic vasodilation in these 
patients. Vasopressin is an effective systemic vasoconstricor but also appears to cause 
profound bronchial vasoconstriction and may cause bronchial ischemia in these patients and 
may affect bronchial anastomotic healing, therefore its use is avoided. 
The incidence of supraventricular arrhythmias are not uncommon following lung 
transplantation (22). The commonest arrhythmias are supraventricular tachycardia and 
atrial fibrillation. Many programs take preventive measures for atrial fibrillation in the post-
operative period which can reduce the incidence of this complication but unlikely to prevent 
it completely. The effects and complication due to atrial fibrillation are systemic 
hypotension and systemic embolization, perhaps made worse by fresh suture line on the left 
atrium. Although amiodarone is generally avoided due to its effects on the lung, we have 
used amidarone in patients who are resistant or unsuitable for treatment with calcium 
channel blockers or beta blockers. Anticoagulation will be necessary as in other patients 
with atrial fibrillation and the biopsy schedules needed to be considered and preferentially 
treated with short acting agents in the post operative period. It will be prudent to check 
clotting studies prior to transbronchial biopsy or endobronchial intervention as 
uncontrollable bronchial hemorrhage is invariably fatal.  
7. Diagnosis and management of early surgical complication 
The major surgical complications are bleeding, anastomotic complications and mal-rotation 
of the graft (24). The latter two are rare with current understanding and experience. 
Bleeding is less common and is due to refinement in surgical techniques, judicious use of 
pharmacological agents and blood products. The patients at high risk are the ones with 
extensive pleural adhesions, large and extensive mediastinal collateral vessels and patients 
with connective tissue disorders with secondary pulmonary hypertension. Patients with 
right heart failure and congested liver or patients on chronic anticoagulation or anti-platelet 
therapy are particularly susceptible and correction of coagulation defect is mandatory in 
these patients. If a patient persists with significant blood loss (>100 cc/hr), for 4-6 hours, the 
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patient needs to return to the operating room unless there is evidence of significant 
coagulation abnormalities. 
The dreaded complication of complete bronchial anastomotic dehiscence is rarely seen now 
but stenosis at the anastomotic site is not that uncommon, being reported between 5-25% of 
the anastomoses. This complication is usually delayed for several weeks following 
transplantation (25). In the presence of anatamotic site infection or significant donor 
bronchial ischemia minor bronchial dehiscence may present as early as 1-2 weeks.  
Vascular anastomotic complications are infrequently reported, and their real incidence may 
be higher than that reported in the literature. The venous complication if severe enough can 
present few hours following transplantation as acute graft dysfunction. This presents as 
rapidly progressing pulmonary edema, with diffuse, dense infiltrate of the affected lung or 
lobe. This is a potentially lethal condition and diagnosis require high index of suspicion. 
TEE is helpful to confirm diagnosis. Surgical correction is required if this is due to 
anatomotic narrowing due to surgical technique. Thrombus formation at the anastomotic 
site can also cause venous obstruction and this is insidious in origin and progressive. 
Thrombolytic agents had been successfully used in these circumstances. Arterial 
anastomotic stenosis presents as hypoxemia, usually associated with exercise. This should 
be suspected if there is no other reason for hypoxemia. Pulmonary angiogram is diagnostic 
and catheter based intervention including stent placement has been successfully employed. 
Mal-rotation of Lobar or lung on its axis is a rare complication and if not corrected 
immediately will result in necrosis of the lobe or lung. Complete opacification of the lobe or 
lung is noted in chest radiograph. Bronchoscopic examination is confirmatory of the 
bronchial torsion. 
8. Pain management 
Patients undergoing thoracic surgery require effective pain relief to allow deep breathing, 
coughing and facilitate early ambulation. In lung transplant patients this becomes crucial as 
they are chronically debilitated and have difficulty clearing secretions. While providing 
effective pain relief it is necessary to prevent sedation to promote early ambulation and 
therefore avoidance of narcotics is preferred. Thoracic epidural analgesia is effective in 
providing pain relief without causing sedation. We advocate placement of the thoracic 
epidural pre-operatively or place it soon after patient is extubated. NSAID are avoided 
because of the potential interactions with other nephrotoxic agents particularly the 
calcineurin inhibitors. Transitioning to oral pain medication is monitored carefully prior to 
discharge from the hospital.  
9. Immunosuppression 
Immunosuppression after lung transplantation includes three major categories of 
immunosuppressive agents; calcineurin inhibitors (tacrolimus, cyclosporine A), 
antimetabolites (azathioprine, mycophenolate mofetil) and corticosteroids. In addition, 
approximately 45% of lung transplant patients receive induction therapy after lung 
transplantation. The calcineurin inhibitors are administered within hours after 
transplantation and may be given either intravenously or sublingually. In general, 
tacrolimus is dosed at 0.05-0.1 mg/ kg over 24 hours by continuous infusion and may also 
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be given sublingually at a dose of 0.03 mg/kg twice daily. Target tacrolimus trough levels 
range between 10-20 ng/ml in the first six months after transplantation, followed by levels 
around 10ng/ml thereafter. Cyclosporine is administered at a rate of 3 mg/kg over 24 hours 
with target trough levels between 350-450 ng/ ml in the first month, between 300-350 ng/ml 
during the first year and between 200-300 ng/ml thereafter. Both of these medications are 
available in oral formulation and should be given orally after extubation. Although current 
data have not shown a superiority of one of the calcineurin inhibitors, there has been an 
increasing use of tacrolimus in the lung transplant population due to reports of improved 
pulmonary function and possibly a reduction in the incidence of bronchiolitis obliterans 
syndrome (26,27). 
Antimetabolites (either azathioprine or mycophenolate mofetil) are the second 
immunosuppressive medication that are used in the treatment of lung transplant recipients.  
The first dose may be initially administered prior to implantation of the lung allograft. 
Azathioprine is dosed at 2mg/kg daily and can be administered either intravenously or 
orally. Mycophenolate mofetil is dosed orally at 2-3 gram in daily divided doses. In general, 
antimetabolites may be associated with myelosuppression and gastrointestinal distress and 
doses may be adjusted based on these side effects. Two randomized multicenter studies that 
have not shown any difference in acute rejection, or survival between these two agents 
(28,29). 
Corticosteroids have been the mainstay of immunosuppression since the advent of 
successful lung transplantation in the 1980s. First dose of methylprednisolone (between 500 
to 1000 mg intravenously) is usually given prior to reperfusion of the graft in the operating 
room. Subsequent doses of corticosteroids range between 0.5-1 mg/kg during the first few 
weeks after transplantation. In general, corticosteroids are tapered to the equivalent of 5-10 
mg of prednisone daily by three to six months after transplantation. 
The role of induction therapy in lung transplantation has yet to be defined. There are several 
different types of induction therapy that are currently being used in lung transplantation 
including the interleukin- 2 receptor antagonists (daclizumab, basiliximab), the polyclonal 
agents(ATGAM, thymoglobulin) and the monoclonal antibody (OKT3). Several reports have 
suggested that induction therapies may reduce the incidence of acute rejection during the 
first six months after lung transplantation. However, longer term outcomes including 
prevention of chronic rejection or improving survival have not been associated with the use 
of induction therapy after lung transplantation (30-32). 
10. Infection prophylaxis 
Infections remain a major source of morbidity and mortality after lung transplantation.  
Prophylaxis against bacterial, viral and fungal organisms usually starts immediately 
postoperatively in the recipients. Initial antibiotic prophylaxis should be directed towards 
adequate anaerobic coverage and tailored towards any positive donor or recipient culture 
detected prior to transplantation. These antibiotics are usually continued between three to 
fourteen days post transplant depending upon the individual transplant center’s protocol.  
Lung transplant recipients with septic lung disease (cystic fibrosis, bronchiectasis) who may 
be colonized with resistant organisms often receive two synergistic antibiotics based on 
prior sensitivities during this time period. 
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Viral prophylaxis is most commonly targeted against cytomegalovirus (CMV). Aggressive 
prophylactic therapy is directed towards this organism because of its high virulence and 
association with mortality in the lung transplant population. Lung transplant recipients 
with either donor or recipient serology that is positive for CMV usually receive 
prophylactic therapy with valganciclovir anywhere between three months to lifelong 
therapy. CMV negative lung transplant recipients who received a CMV positive donor 
lung may also receive CMV immunoglobulin in addition to their current valganciclovir 
therapy. Unfortunately, while valganciclovir prophylaxis decreases the incidence of CMV 
infection during the time of administration, prophylaxis does not completely prevent the 
development of CMV infection especially after prophylaxis therapy is discontinued. The 
optimal duration and type of therapy are still a matter of debate. Acyclovir and its 
derivatives are given to CMV negative lung transplant recipients who receive CMV 
negative donors in order to prevent the development of Herpes infections. 
Fungal prophylaxis varies among the different transplant centers depending upon  
prior colonization, mechanical airway complications and environmental factors. In 
general some centers provide general fungal prophylaxis while others consider 
preemptive therapy depending upon surveillance bronchoscopy findings. Lung 
transplant recipients are at increased risk for developing Aspergillus spp. colonization of 
the airways leading to anastomotic infections and ulcerative tracheobronchitis. 
Itraconazole (or other azole substitutes) and inhaled amphotericin are the most common 
fungal prophylactic agents that are currently used. The azoles will increase the levels of 
the calcineurin inhibitors (cyclosporine and tacrolimus) so that the doses of these 
immunosuppressive medications should be decreased by at least 1/3 of their original 
dose. Calcineurin levels should be checked approximately one week after starting an 
azole. Of note, voriconazole and sirolimus should not be used together due to the 
significant rise in sirolimus levels. 
11. Transplant outcomes 
Significant improvements have been achieved in the past two decades with organ 
preservation, surgical techniques, critical care and immunosuppression. At present over 
80% of patients receiving a lung transplant for end-stage lung disease are alive at 1 year and 
half of them are at 5 years (33). There are differences in the survival for different etiology for 
the underlying end-stage lung disease (Figure 1). Primary graft dysfunction is an important 
cause of post-operative mortality (33). The major cause of early and late mortality is 
infectious complications and bronchiolitis obliterans, a condition of progressive airflow 
obstruction associated with chronic airway fibrosis a pathologic finding known as 
bronchiolitis obliterans (BO). Majority of the late mortality is directly or indirectly due to the 
development of bronchiolitis obliterans syndrome or OB (Table 2) (34,35). Although the 
pathological mechanism that lead to BO is not well understood there have been many 
associations reported. A significant predictor of OB is prior acute rejection. Other conditions 
are primary graft dysfunction, gastroesophageal reflux or infections (36). Currently there are 
few well established therapies available for prevention or treatment of OB. Ongoing 
research continues to advance our understanding of the pathogenesis which may lead to 
effective treatment strategies in the future.  
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Fig. 1. Kaplan-Meier survival by diagnosis for adult lung transplants performed between 
January 1990 and June 2008. AT Def, α1-antitrypsin deficiency emphysema; CF, cystic 
fibrosis; COPD, chronic obstructive pulmonary disease; IPAH, idiopathic pulmonary arterial 
hypertension; IPF, idiopathic pulmonary fibrosis. 
J Heart Lung Transplant. 10: 1083-1141, 2010  
 
 0–30 days 31 days–1 year >1–3 years >3–5 years >5–10 years >10 years 
 (n = 1,966) (n = 3,387) (n = 3,073) (n = 1,737) (n = 2,014) (n = 483) 
Cause of death No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Bronchiolitis 6 (0.3) 159 (4.7) 781 (25.4) 508 (29.2) 507 (25.2) 95 (19.7) 
Acute rejection 74 (3.8) 61 (1.8) 48 (1.6) 10 (0.6) 15 (0.7) 1 (0.2) 
Lymphoma 1 (0.1) 86 (2.5) 63 (2.1) 28 (1.6) 46 (2.3) 23 (4.8) 
Other malignancy 4 (0.2) 100 (3.0) 202 (6.6) 151 (8.7) 219 (10.9) 47 (9.7) 
Infection       
CMV 0 96 (2.8) 29 (0.9) 5 (0.3) 4 (0.2) 0 
Non-CMV 396 (20.1) 1,205 (35.6) 710 (23.1) 329 (18.9) 363 (18.0) 81 (16.8) 
Graft failure 557 (28.3) 589 (17.4) 591 (19.2) 327 (18.8) 379 (18.8) 87 (18.0) 
Cardiovascular 213 (10.8) 144 (4.3) 118 (3.8) 82 (4.7) 99 (4.9) 36 (7.5) 
Technical 162 (8.2) 76 (2.2) 18 (0.6) 8 (0.5) 12 (0.6) 6 (1.2) 
Other 553 (28.1) 871 (25.7) 513 (16.7) 289 (16.6) 370 (18.4) 107 (22.2) 
Table 2. Causes of Death Following Lung Transplantation in Adult Recipients. 
J Heart Lung Transplant. 10: 1083-1141, 2010  
13. Conclusion 
Lung transplant remains an effective treatment for selected patients with end-stage lung 
disease. The major rate limiting step for lung transplantation at present is the available 
donor organs. Chronic allograft dysfunction remains a major source of morbidity and 
mortality after lung transplantation. Investigations into improving donor lung availability, 
preventive and therapeutic approaches for OB and alternative for transplantation for end-
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stage lung disease are subjects currently under intense investigation aimed at improving 
short and long term result of therapy for end-stage lung disease. 
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